BMS employees ride across Europe for UICC

25 July 2016

Bristol-Myers Squibb (BMS) is launching an epic European cycling event in support of the Union for International Cancer Control (UICC), to accelerate the fight against cancer and improve the quality of life for cancer patients. 

After the great success of the 2015 US Coast to Coast for Cancer Ride, employees from Bristol-Myers Squibb (BMS) in Europe are completing a ride of over 4,000 km across the United Kingdom, France, Spain, Italy, Switzerland and Germany to raise funds for cancer patients globally and support the UICC.

In this European edition of the ride, which starts on 10 September 2016 and lasts 18 days, 75 European BMS team members will be riding as part of six country teams. Each group will be performing a leg of the ride averaging 450 km over 3 to 4 days. 

These participants are novice riders, who have committed themselves to five months of intensive training to complete their portion of the ride. Some participants are cancer survivors; others have witnessed the devastating impact of cancer on friends and family. Their kilometres will help raise funds and support UICC's mission of uniting communities to reduce the global cancer burden.   

"It is such a privilege to ride for cancer patients. The event is a true testament to never underestimating the power of the human spirit. When faced with difficulty and adversity, know that you can conquer it and you will," explains Linda Karrer, rider for the 2015 US edition.

"This was my chance to show my support for those battling cancer. Some have fought the battle and won, others have not been so lucky, and others are fighting the battle of their lives. For these people, I will fight through this" adds Stefani Cunniungham, rider for the 2015 US edition.

Cancer is one of the leading causes of death worldwide. Each year, there are 14 million new cases and 8.2 million cancer-related deaths, and these numbers are growing. Within the next two decades, the number of new cancer cases is estimated to rise to 22 million. This is the reason why BMS has chosen to support UICC in its mission to unite the global cancer community and advocate so that cancer is considered a priority for governments around the world. 

We thank BMS for selecting UICC as the recipient for the C2C4C European ride and sincerely appreciate their employees' commitment to supporting our mission.

To discover the six BMS teams and donate, please visit causedirect.org/en/company/c2c4c-ride.


About Bristol-Myers Squibb

BMS is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information please visit www.bms.com.

Last update: 
Monday 22 May 2017
Share